Temple acquires London longevity practice Longevous ahead of wearable launch

Deepinder Goyal-led healthtech startup Temple has acquired London-based Longevous, bringing its founders in as chief medical officer and head of science as it prepares to launch a longevity-tracking wearable within the next year.

— Source publishedThu, 27 Aug, 2026, 15:59 IST·First seen Thu, 27 Aug, 2026, 16:02 IST·Source Entrackr · Newsletter

What happened

Deepinder Goyal-led healthtech startup Temple acquired London longevity-medicine practice Longevous, adding its founders as chief medical officer and head of

Key facts

  • $375 million valuation
  • two months
  • nearly two decades of clinical experience
  • within the next year

Why this matters

Temple used a talent-and-capability acquisition to secure longevity science expertise and accelerate its wearable-market entry rather than building the function internally.

What to watch

  • Announcement of the wearable's sensors, biomarker capabilities, pricing and subscription structure.
  • Clinical studies, validation data or partnerships with hospitals, labs, insurers or corporate-wellness platforms.
  • Whether Temple offers blood testing, clinician consultations or prescription-adjacent services alongside the device.
  • Regulatory classification, privacy policy and language used around disease prevention, biological age and medical recommendations.
  • Hiring in hardware engineering, regulatory affairs, AI/data science and consumer growth.
  • Evidence of launch-market selection beyond the UK and of a strategy to acquire customers outside Longevous' existing practice base.
  • Retention and recurring-revenue indicators from any early membership or pilot program.
  • Integrate Longevous founders into product, clinical-governance and claims-review functions.
  • Build a longitudinal dataset combining wearable signals, lab results, lifestyle inputs and practitioner outcomes.
  • Pilot a paid membership model bundling the device with diagnostics, telehealth, coaching and follow-up testing.
  • Recruit clinical advisors, research partners and possibly private clinics to validate protocols before launch.
  • Set conservative initial marketing claims and invest in consent, data-security and medical-device compliance infrastructure.
  • Use the Longevous customer base as an early-access cohort for device testing and retention experiments.

Also reported by